Aridis Pharmaceuticals Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Vu Truong

Chief executive officer

US$752.5k

Total compensation

CEO salary percentage	69.8%
CEO tenure	21.3yrs
CEO ownership	1.5%
Management average tenure	no data
Board average tenure	7.8yrs

Recent management updates

Recent updates

Aridis Pharmaceuticals announces proposed public stock offering; shares down ~30%

Sep 26

Aridis Pharmaceuticals GAAP EPS of -$0.45, revenue of $0.29M

Aug 16

Can You Imagine How Aridis Pharmaceuticals' (NASDAQ:ARDS) Shareholders Feel About The 32% Share Price Increase?

Feb 17

Aridis Pharmaceuticals EPS misses by $0.02

Nov 20

Aridis Pharmaceuticals (ARDS) Investor Presentation - Slideshow

Oct 31

CEO Compensation Analysis

How has Vu Truong's remuneration changed compared to Aridis Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2023	n/a	n/a	-US$1m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$753k	US$525k	-US$30m
Sep 30 2022	n/a	n/a	-US$33m
Jun 30 2022	n/a	n/a	-US$49m
Mar 31 2022	n/a	n/a	-US$46m
Dec 31 2021	US$842k	US$500k	-US$46m
Sep 30 2021	n/a	n/a	-US$43m
Jun 30 2021	n/a	n/a	-US$25m
Mar 31 2021	n/a	n/a	-US$24m
Dec 31 2020	US$783k	US$475k	-US$22m
Sep 30 2020	n/a	n/a	-US$22m
Jun 30 2020	n/a	n/a	-US$24m
Mar 31 2020	n/a	n/a	-US$28m
Dec 31 2019	US$2m	US$450k	-US$30m
Sep 30 2019	n/a	n/a	-US$29m
Jun 30 2019	n/a	n/a	-US$30m
Mar 31 2019	n/a	n/a	-US$23m
Dec 31 2018	US$2m	US$450k	-US$23m
Sep 30 2018	n/a	n/a	-US$24m
Jun 30 2018	n/a	n/a	-US$22m
Mar 31 2018	n/a	n/a	-US$27m
Dec 31 2017	US$490k	US$350k	-US$27m

Compensation vs Market: Vu's total compensation ($USD752.52K) is about average for companies of similar size in the US market ($USD663.90K).

Compensation vs Earnings: Vu's compensation has been consistent with company performance over the past year.

CEO

Vu Truong (59 yo)

21.3yrs

Tenure

US$752,516

Compensation

Dr. Vu L. Truong, Ph D., is the Founder at Aridis Pharmaceuticals, Inc. and also serves as its Chief Executive Officer and Chief Scientific Officer since 2003. He has more than 15 years of experience in b...

Board Members

Name	Position	Tenure	Compensation	Ownership
Eric Patzer	Founder & Executive Chairman	19.3yrs	US$262.80k	1.46% $ 43.2k
Vu Truong	Founder	10.3yrs	US$752.52k	1.54% $ 45.3k
John Patton	Member of the Scientific Advisory Board	no data	no data	no data
John Hamilton	Independent Director	8.9yrs	US$40.50k	0.0042% $ 122.9
Harry Greenberg	Member of Scientific Advisory Board	no data	no data	no data
Susan Windham-Bannister	Independent Director	4.9yrs	US$37.50k	0% $ 0
Marin Kollef	Member of Clinical Advisory Board	7.8yrs	no data	no data
Alan Cohen	Member of Clinical Advisory Board	no data	US$703.17k	no data
Jerry Pier	Member of the Scientific Advisory Board	no data	no data	no data
Steven Opal	Member Scientific Advisory Board	no data	no data	no data
Bruno Francois	Member of Clinical Advisory Board	7.8yrs	no data	no data
Jean Chastre	Member of Clinical Advisory Board	7.8yrs	no data	no data

7.8yrs

Average Tenure

72yo

Average Age

Experienced Board: ARDS's board of directors are considered experienced (7.8 years average tenure).

Aridis Pharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

Aridis Pharmaceuticals, Inc., Annual General Meeting, Dec 15, 2023

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Aridis Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2022

Recent updates

Aridis Pharmaceuticals, Inc., Annual General Meeting, Dec 15, 2023

Nasdaq To File A Form 25 with the Securities and Exchange Commission to Complete the Delisting Common Stock of Aridis Pharmaceuticals

Aridis Pharmaceuticals Common Stock to Delist from Nasdaq Capital Market on July 19

Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation

Aridis Pharmaceuticals, Inc. Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design

Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q

Aridis Pharmaceuticals, Inc. announced delayed 10-Q filing

Price target decreased by 43% to US$6.00

Insufficient new directors

Aridis Pharmaceuticals, Inc. Announces Top-Line Results from the AR-301-002 Phase 3 Study

Aridis Pharmaceuticals, Inc. Announces New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update

Aridis Pharmaceuticals, Inc. announced that it has received $4.848271 million in funding from Cystic Fibrosis Foundation

Aridis Announces A Key Milestone of Closing of Patient Enrollment in the Phase 2A Study of AR-501 in Cystic Fibrosis Patients

Aridis Pharmaceuticals, Inc. announced delayed 10-Q filing

Insufficient new directors

Aridis Pharmaceuticals, Inc. announced that it has received $8 million in funding

Aridis Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Aridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority Study

Aridis Pharmaceuticals announces proposed public stock offering; shares down ~30%

Aridis Pharmaceuticals, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

Aridis Pharmaceuticals GAAP EPS of -$0.45, revenue of $0.29M

Aridis Pharmaceuticals, Inc. Announces its Inhaled Treatment of its Fully Human Monoclonal Antibody Cocktail AR-701 Resulted in No Detectable SARS-CoV-2 Virus in the Lungs of Infected Rhesus Macaques, and Protected Their Lungs from Disease

Insufficient new directors

Insufficient new directors

Price target decreased to US$9.67

No longer forecast to breakeven

Aridis Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2022

Aridis Pharmaceuticals Receives Written Notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding Minimum Market Value Requirement

Aridis Pharmaceuticals, Inc. announced delayed annual 10-K filing

Aridis Pharmaceuticals, Inc. Provides Update on its Pan-Coronavirus Monoclonal Antibody Cocktail AR-701 in COVID-19 Omicron Infected Animals

Aridis Pharmaceuticals, Inc. Receives Funding to Evaluate Inhaled Monoclonal Antibodies to Block Influenza and SARS-CoV-2 Transmission

No longer forecast to breakeven

Aridis Pharmaceuticals Announces a Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS, and the Common Cold Human Coronaviruses

Consensus revenue estimates fall by 20%

Price target decreased to US$15.00

Price target increased to US$19.00

Aridis Pharmaceuticals, Inc. Announces Covid mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant

Chief Financial Officer Michael Nazak has left the company

Consensus forecasts updated

Consensus forecasts updated

Aridis Pharmaceuticals, Inc. Enters into Out-Licensing and Product Discovery Agreement with Kermode Biotechnologies, Inc

Aridis Pharmaceuticals Provides Multiple Program Updates Including the Addition of A Second Inhaled Antibody to Neutralize Newly Emerging Covid-19 Mutated Variants

Can You Imagine How Aridis Pharmaceuticals' (NASDAQ:ARDS) Shareholders Feel About The 32% Share Price Increase?

New 90-day high: US$8.08

Aridis Pharmaceuticals EPS misses by $0.02

Aridis Pharmaceuticals, Inc. announced delayed 10-Q filing

Aridis Pharmaceuticals (ARDS) Investor Presentation - Slideshow

New 90-day low: US$6.38

New 90-day high: US$8.01

Aridis Pharmaceuticals, Inc. to Present At the H.C. Wainwright 21 Annual Global Investment Conference on September 10, 2019

Analysts increase revenue estimates to US$1.63m

CEO Compensation Analysis

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age